Randomized Trialhigh evidence
Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea.
The New England journal of medicine·October 21, 2026·PMID 42904878
Why it mattersOSA in patients with obesity is common and often undertreated; current therapies like CPAP have adherence challenges. Retatrutide, a triple agonist, offers a potential pharmacologic option that addresses both weight and AHI, with clinically meaningful reductions in sleep apnea severity.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled